Out of the three glycolytic genes, PFKM (p < 0.05) showed significant upregulation in higher-grade tumors as compared to low-grade tumors as indicated in Table 3 and Figure 2E. Significant overexpression of the glycolytic genes HK2 and PKM2 (p < 0.05) was observed in advanced clinical stages (stage III/IV) of breast cancer as compared to early stages (stage I/II), as shown in Figure 1F and Figure 3F. Comparably, significant overexpression of the PFKM gene (p < 0.05) was seen in the early clinical stages (SI/II) of breast cancer. Here, PKM is linked to breast carcinoma.